National Toxicology Program Division
The NTP Associate Director’s Office provides scientific leadership for NTP. The offices supporting the Associate Director and the NTP Division:
- Foster a productive environment for research, testing, and analysis activities
- Promote interactions and coordination among NTP and NIEHS staff
- Serve as liaisons with other NTP federal partner agencies and with the Department of Health and Human Services
- Serves as focal point for NTP Postdoctoral training opportunities
The Associate Director of NTP
The Associate Director provides policy, analytical, and scientific leadership for the National Toxicology Program (NTP) and for planning, managing, and coordinating all of NTP’s internal and external activities.
- Brian R. Berridge, D.V.M., Ph.D., D.A.C.V.P.
Associate Director, National Toxicology Program
Scientific Director, National Toxicology Program Division
- Tel 984-287-3111
- P.O. Box 12233Mail Drop K2-02Durham, N.C. 27709
Brian Berridge, D.V.M., Ph.D., D.A.C.V.P., joined the NIH in January of 2018 as the Associate Director of the National Toxicology Program (NTP) and the Scientific Director of the NTP Division at the National Institute of Environmental Health Sciences. Previous to NIEHS, Berridge spent 17 years in the pharmaceutical industry in varying roles as a toxicologic pathologist at Eli Lilly in Indianapolis, Indiana, and GlaxoSmithKline in Research Triangle Park, North Carolina.
Berridge is an Oklahoma State University-trained veterinarian with residency and Ph.D. training from Texas A&M University. He is a Diplomate of the American College of Veterinary Pathologists with post-doctoral training in comparative cardiovascular pathology from the Texas Heart Institute in Houston, Texas. His areas of interest and expertise include toxicologic and comparative pathology with particular interest in cardiovascular and renal pathology. He is a veteran of the U.S. Air Force where he was a non-commissioned officer trained as a histopathology and electron microscopy technologist. Berridge is currently active in various consortium efforts aimed at advancing innovative approaches to modeling human pathobiology that improve the translation of preclinical research to clinical outcomes and advance our ability to characterize human cardiovascular health hazards.